Uhlig Christopher, Spieth Peter Markus
Anasthesiol Intensivmed Notfallmed Schmerzther. 2018 Nov;53(11-12):787-792. doi: 10.1055/s-0043-124906. Epub 2018 Nov 20.
The therapy of patients suffering from sepsis and septic shock is one of the greatest challenges in critical care medicine. In the initial phase of septic shock patients often present with hyperdynamic circulatory conditions with elevated cardiac index, tachycardia and progressive hemodynamic instability. The type of tachycardia differs from atrial fibrillation or flatter to sinus tachycardia. The latter might be persistent even in case of adequate volume therapy according to the surviving sepsis campaign recommendations and may represent an independent pathology due to adrenergic overstimulation. Despite predominantly β-mediated immunomodulatory effects the administration of a selective β-adrenergic blocker may be beneficial in some cases. On the other hand, incautious administration of beta-blockers especially in case of insufficient volume replacement may result in direct negative inotropic effects rapidly aggravating hypotension and shock. This review focused on pharmacology of the β-adrenergic system, the pathophysiological rationale and current literature on clinical practice of the use of beta-blockers in sepsis and septic shock.
脓毒症和脓毒性休克患者的治疗是重症医学面临的最大挑战之一。在脓毒性休克的初始阶段,患者常表现为高动力循环状态,心脏指数升高、心动过速且血流动力学逐渐不稳定。心动过速的类型从房颤或更缓的心律到窦性心动过速不等。即使根据拯救脓毒症运动的建议进行了充分的容量治疗,后者仍可能持续存在,并且可能由于肾上腺素能过度刺激而代表一种独立的病理状态。尽管主要是β介导的免疫调节作用,但在某些情况下,给予选择性β肾上腺素能阻滞剂可能有益。另一方面,尤其是在容量补充不足的情况下,不谨慎地使用β受体阻滞剂可能会导致直接的负性肌力作用,迅速加重低血压和休克。本综述聚焦于β肾上腺素能系统的药理学、病理生理学原理以及关于在脓毒症和脓毒性休克中使用β受体阻滞剂的临床实践的当前文献。